“…Quercetin has antihistamine, antiviral, immunomodulatory, and antioxidant properties and recently it has shown antitumor activity, which can induce apoptosis of different tumor cells including leukemic cells, medullary and papillary thyroid cancer, pancreatic tumor, breast cancer, hepatocarcinoma, prostate cancer, and glioblastoma (Pan et al, ; Vidak, Rozman, & Komel, ). Its mechanism of action is principally based on the cell cycle regulation, tyrosine kinase inhibition (Quagliariello, Armenia, et al, ) inhibition of cytokine and interleukin secretion (Quagliariello, Iaffaioli, et al, ), AMPK‐Sclerosis Tuberous Complex (TSC) activation and AKT‐mTOR axis inhibition (Lu et al, ) but the main clinical limitation is based on its low bioavailability due to oxidation in biological environment with a not efficient accumulation in cancer cell cytoplasm (Nam et al, ). On the basis of these limitations it would be useful to develop nanocarriers to enhance quercetin delivery protecting it from the oxidative and enzymatic environment and simultaneously achieving a more specific and controlled release in glioblastoma cells.…”